Literature DB >> 26976858

Adverse Events Lead to Drug Discontinuation More Commonly among Patients Who Receive Nafcillin than among Those Who Receive Oxacillin.

J Alexander Viehman1, Louise-Marie Oleksiuk2, Kathleen R Sheridan1, Karin E Byers1, Peimei He3, Bonnie A Falcione1, Ryan K Shields4.   

Abstract

Nafcillin and oxacillin are used interchangeably in clinical practice, yet few studies have evaluated the safety of these two agents. Our objective was to compare the differential tolerabilities of nafcillin and oxacillin among hospitalized patients. We conducted a retrospective cohort study of all patients who received 12 g/day of nafcillin or oxacillin for at least 24 h. Two hundred twenty-four patients were included. Baseline characteristics and comorbidities were similar among patients receiving nafcillin (n = 160) and those receiving oxacillin (n = 64). Hypokalemia, defined as a potassium level of ≤3.3 mmol/liter or ≤2.9 mmol/liter or as a ≥0.5-mmol/liter decrease from the baseline level, occurred more frequently among patients who received nafcillin (51%, 20%, and 56%, respectively) than among those who received oxacillin (17%, 3%, and 34%, respectively; P < 0.0001, P = 0.0008, and P = 0.005, respectively). By multivariate logistic regression analysis, receipt of nafcillin was an independent predictor of severe hypokalemia (odds ratio [OR] = 6.74; 95% confidence interval [CI], 1.46 to 31.2; P = 0.02). Rates of hepatotoxicity did not differ between groups; however, acute kidney injury occurred more commonly with nafcillin than with oxacillin (18% versus 6%; P = 0.03). Overall, 18% of patients who received nafcillin discontinued therapy prematurely due to adverse events, compared to 2% of patients who received oxacillin (P = 0.0004). Nafcillin treatment is associated with higher rates of adverse events and treatment discontinuation than oxacillin among hospitalized adult patients. These findings have important implications for patients in both inpatient and outpatient settings, particularly patients who require long-term therapy and cannot be monitored routinely. Future randomized controlled studies evaluating the efficacy, costs, and tolerability of nafcillin versus oxacillin are warranted.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26976858      PMCID: PMC4862451          DOI: 10.1128/AAC.03122-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

1.  A retrospective comparison of ceftriaxone versus oxacillin for osteoarticular infections due to methicillin-susceptible Staphylococcus aureus.

Authors:  Brent W Wieland; Jodie R Marcantoni; Kerry M Bommarito; David K Warren; Jonas Marschall
Journal:  Clin Infect Dis       Date:  2011-12-05       Impact factor: 9.079

2.  Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia.

Authors:  Sung-Han Kim; Kye-Hyung Kim; Hong-Bin Kim; Nam-Joong Kim; Eui-Chong Kim; Myoung-don Oh; Kang-Won Choe
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

3.  Impact of empirical-therapy selection on outcomes of intravenous drug users with infective endocarditis caused by methicillin-susceptible Staphylococcus aureus.

Authors:  Thomas P Lodise; Peggy S McKinnon; Donald P Levine; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2007-07-30       Impact factor: 5.191

4.  Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals.

Authors:  Jennifer S McDanel; Eli N Perencevich; Daniel J Diekema; Loreen A Herwaldt; Tara C Smith; Elizabeth A Chrischilles; Jeffrey D Dawson; Lan Jiang; Michihiko Goto; Marin L Schweizer
Journal:  Clin Infect Dis       Date:  2015-04-21       Impact factor: 9.079

Review 5.  KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury.

Authors:  Paul M Palevsky; Kathleen D Liu; Patrick D Brophy; Lakhmir S Chawla; Chirag R Parikh; Charuhas V Thakar; Ashita J Tolwani; Sushrut S Waikar; Steven D Weisbord
Journal:  Am J Kidney Dis       Date:  2013-03-15       Impact factor: 8.860

6.  Nafcillin-induced interstitial nephritis.

Authors:  T W Bodendorfer
Journal:  JAMA       Date:  1980-12-12       Impact factor: 56.272

7.  Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials.

Authors:  Nizar F Maraqa; Margarita M Gomez; Mobeen H Rathore; Ana M Alvarez
Journal:  Clin Infect Dis       Date:  2001-11-26       Impact factor: 9.079

Review 8.  Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.

Authors:  Steven Y C Tong; Joshua S Davis; Emily Eichenberger; Thomas L Holland; Vance G Fowler
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

9.  Ticarcillin associated hypokalemia.

Authors:  A A Nanji; J Lindsay
Journal:  Clin Biochem       Date:  1982-04       Impact factor: 3.281

10.  Hypokalaemia, metabolic alkalosis, and hypernatraemia due to "massive" sodium penicillin therapy.

Authors:  F P Brunner; P G Frick
Journal:  Br Med J       Date:  1968-11-30
View more
  8 in total

1.  Disproportionality Analysis of Safety with Nafcillin and Oxacillin with the FDA Adverse Event Reporting System (FAERS).

Authors:  Tristan T Timbrook; Lydia McKay; Jesse D Sutton; Emily S Spivak
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin.

Authors:  Khalid Eljaaly; Samah Alshehri; Brian L Erstad
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 3.  Drug-Induced Kidney Injury in the Elderly.

Authors:  Sana Khan; Valentina Loi; Mitchell H Rosner
Journal:  Drugs Aging       Date:  2017-10       Impact factor: 3.923

4.  Comparative Effectiveness of Exclusive Exposure to Nafcillin or Oxacillin, Cefazolin, Piperacillin/Tazobactam, and Fluoroquinolones Among a National Cohort of Veterans With Methicillin-Susceptible Staphylococcus aureus Bloodstream Infection.

Authors:  Maya Beganovic; Jaclyn A Cusumano; Vrishali Lopes; Kerry L LaPlante; Aisling R Caffrey
Journal:  Open Forum Infect Dis       Date:  2019-06-06       Impact factor: 3.835

5.  The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.

Authors:  Lauren K Flynt; Rachel M Kenney; Marcus J Zervos; Susan L Davis
Journal:  Infect Dis Ther       Date:  2017-03-06

6.  Risk Factors Associated With Outpatient Parenteral Antibiotic Therapy Program Failure Among Intravenous Drug Users.

Authors:  Deanna J Buehrle; Ryan K Shields; Neel Shah; Christopher Shoff; Kathleen Sheridan
Journal:  Open Forum Infect Dis       Date:  2017-05-23       Impact factor: 3.835

7.  A Patient with Nafcillin-Associated Drug-Induced Liver Failure.

Authors:  Qin Rao; Isaiah Schuster; Talal Seoud; Kevin Zarrabi; Nirvani Goolsarran
Journal:  Case Rep Gastroenterol       Date:  2017-09-26

8.  Incidence and Determinants of Piperacillin/Tazobactam-Associated Hypokalemia: A Retrospective Study.

Authors:  Heenam Seo; Eunyoung Kim
Journal:  Antibiotics (Basel)       Date:  2022-08-22
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.